C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 217/54 (2006.01) A61K 31/00 (2006.01) A61K 31/137 (2006.01) A61K 31/277 (2006.01) A61K 31/341 (2006.01) A61K 31/381 (2006.01) A61K 31/40 (2006.01) A61K 31/4164 (2006.01) A61K 31/42 (2006.01) A61K 31/421 (2006.01) A61K 31/426 (2006.01) A61K 31/44 (2006.01) A61K 31/4402 (2006.01) A61K 31/4406 (2006.01) A61K 31/445 (2006.01) A61K 31/4453 (2006.01) A61K 31/4462 (2006.01) A61K 31/4965 (2006.01) A61K 31/505 (2006.01) A61K 31/5375 (2006.01) A61P 29/00 (2006.01) A61P 43/00 (2006.01) C07C 211/49 (2006.01) C07C
Patent
CA 2397234
There is disclosed the use of a compound of formula (I) wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.
L'invention concerne l'utilisation d'un composé de la formule (I) où R?1¿, R?2¿, X, Y V, W et Z ont la signification donnée dans la description, de ses sels pharmaceutiquement acceptables, de ses énantiomères ou racémates, pour la production d'un médicament destiné au traitement et à la prévention de maladies ou d'états dans lesquels l'inhibition de l'activité de la synthétase d'oxyde nitrique est bénéfique. L'invention concerne également certains nouveaux composés de la formule (Ia), leurs sels pharmaceutiquement acceptables ainsi que leurs énantiomères et racémates. L'invention concerne enfin leurs procédés de préparation, les compositions les contenant et leur utilisation en thérapie. Les composés des formules (I) et (Ia) sont inhibiteurs de l'enzyme synthétase d'oxyde nitrique et sont donc particulièrement utiles dans le traitement ou la prévention de maladies inflammatoires.
Cheshire David
Connolly Stephen
Cox David
Hamley Peter
Mete Antonio
Astrazeneca Ab
Fetherstonhaugh & Co.
LandOfFree
Novel use of phenylheteroalkylamine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel use of phenylheteroalkylamine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel use of phenylheteroalkylamine derivatives will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1825742